Latest news

• NICE backs first cannabis-based drugs, both from GW Pharma

  2014. NICE turned down Epidyolex in  draft guidance, but has changed its stance after a price reduction from the manufacturer. ... Oral liquid  Epidyolex was approved in Europe for severe epilepsy in September, becoming the first drug to be approved

• GW Pharma’s Epidyolex gets EU approval for severe epilepsy

  Epidyolex could provide a licensed option that doctors will feel more comfortable prescribing, provided GW Pharma can secure NICE’s backing for NHS prescribing of the drug. ... The company – which has said it intends to launch Epidyolex in France,

• Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate

  Judgement arrives ahead of European approval. GW Pharma’s Epidyolex for two types of severe treatment-resistant epilepsy has been given a preliminary rejection by England’s NICE – but the cost ... NICE’s draft guidance issued today is remarkable

• CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

  GW Pharma’s Epidyolex also on the recommended list. Bayer’s Vitrakvi has become the first drug in Europe recommended to treat cancer based on a molecular signature, rather than where ... The CHMP has also granted a positive opinion for GW Pharma’s